Valenta Consolidates Its Neuropsychological Portfolio

Valenta Consolidates Its Neuropsychological Portfolio


Valenta received registration certificate for a medicine of its neuropsychological portfolio, which is intended for treatment of adult patients for Parkinson’s syndrome and extra-pyramid side-effect symptoms (EPS) with neuroleptics or similarly acting medicines.

According to WHO, parkinsonism prevalence is 60 to 187 persons per 100,000 of population. The risk of the syndrome development essentially grows with age: 1% of people under 60 years and about 5% of people over 60 are subject to this disease. Parkinsonism is a neurologic syndrome characterized by tremor, muscular rigidity1, postural imbalance (inability to keep balance, problems with walking, falls) and bradykinesia (slowed-down movements, difficulty with starting movement and turns)2. Antipsychotic medicines were the first medicines widely used to treat parkinsonism. However, it was proved that these medicines promote development of side-effect symptoms at long-term therapy. Thus, in 2013, meta-analysis including 212 clinical trials and involving 43,049 patients showed that all antipsychotics caused extra-pyramid side-effect symptoms (EPS). Valenta’s new registered medicine prevents EPS development due to selective blockade of muscarinic (М1) receptors. This medicine features soft therapeutic action and its abuse is rather seldom.

Andrey Agafonov, Head of Neuropsychological Portfolio Promotion Department, JSC «Valenta Pharm»: «Development of innovations and creation of effective medicines is the key priority of our activity. Valenta adheres to research of neuropsychological diseases and opportunities to improve patient care. Registration in Russia of a new medicine for Parkinson’s syndrome, and its implementation in daily clinical practice will help to improve the life quality of patients with neurologic disorders in our country.»

  • 1 Steady increase of muscle tone, uniform level of muscle resistance in all phases of passive movement equally expressed in flexors and extensors.
  • 2 Parkinson’s Disease // E.I. Gusev, A.N.Konovalova, G.S. Burd. Neurology and Neurosurgery: Textbook. — 2014.
  • 3 Comparison of Effectiveness and Tolerance of 15 Antipsychotic Medicines for Schizophrenia: Meta-Analysis of Comprehensive Therapy, Stefan Leucht. September 2013.
  • 4 Comparative Study of Effectiveness and Tolerance of Biperiden and Trihexyphenidyl, Neuroleptic Therapy Correctors, in Clinical Practice // O.O. Papsuev. Social and Clinical Psychiatry. — 2014, V. 24, No.4